Literature DB >> 27658031

Evaluation of copeptin and commonly used laboratory parameters for the differential diagnosis of profound hyponatraemia in hospitalized patients: 'The Co-MED Study'.

Nicole Nigro1,2, Bettina Winzeler1,2, Isabelle Suter-Widmer1,2, Philipp Schuetz2,3, Birsen Arici1,2, Martina Bally2,3, Claudine A Blum2,3, Christian H Nickel2,4, Roland Bingisser2,4, Andreas Bock2,5, Andreas Huber2,6, Beat Müller2,3, Mirjam Christ-Crain1,2.   

Abstract

OBJECTIVE: Hyponatraemia is common and its differential diagnosis is challenging. Commonly used diagnostic algorithms have limited diagnostic accuracy. Copeptin, the c-terminal portion of the precursor peptide of arginine vasopressin might help in the differential diagnosis of hyponatraemia.
DESIGN: Prospective multicentre observational study. PATIENTS/
METHODS: A total of 298 patients admitted with profound hypoosmolar hyponatraemia (Na < 125 mmol/l) were evaluated. Three experts uninvolved in the patients' care determined the aetiology of hyponatraemia after standardized diagnostic evaluation.
RESULTS: Hyponatraemia differential diagnoses were as follows: syndrome of inappropriate antidiuresis (SIAD), 106 patients (35·6%); 'diuretic-induced', 72 (24·2%); 'hypovolaemic', 59 (19·8%); 'hypervolaemic', 33 (11·1%); primary polydipsia (PP), 24 (8·1%); and cortisol deficiency, 4 (1·3%). Copeptin levels <3·9 pmol/l identified patients with PP with high specificity (91%). Further, copeptin levels >84 pmol/l were highly predictive for hypovolaemic hyponatraemia (specificity: 90%). Urinary sodium levels and copeptin/urinary sodium ratio in patients with SIAD were higher and lower as compared to other hyponatraemia aetiologies (P < 0·0001). However, the specificity to identify SIAD was moderate for both parameters (31% and 61%). Fractional uric acid excretion (FEUA ) and fractional urea excretion (FEurea ) were higher in patients with SIAD compared to other hyponatraemia aetiologies (both P < 0·0001). FEurea values >55% and FEUA values >12% had a specificity of 96% and 77% to detect patients with SIAD. These results remained similar after excluding patients taking diuretics.
CONCLUSIONS: Overall, there is only limited diagnostic utility of copeptin in the differential diagnosis of profound hyponatraemia. Very low copeptin levels are seen in patients with PP and highest copeptin levels in hypovolaemic hyponatraemia. To discriminate between SIAD and other hyponatraemia aetiologies, FEurea and FEUA levels are valuable irrespective of diuretics use.
© 2016 John Wiley & Sons Ltd.

Entities:  

Mesh:

Substances:

Year:  2016        PMID: 27658031     DOI: 10.1111/cen.13243

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  12 in total

Review 1.  Hyponatraemia - presentations and management.

Authors:  Rosemary Dineen; Christopher J Thompson; Mark Sherlock
Journal:  Clin Med (Lond)       Date:  2017-06       Impact factor: 2.659

Review 2.  [Hyponatremia in emergency admissions - often dangerous].

Authors:  W Fenske
Journal:  Internist (Berl)       Date:  2017-10       Impact factor: 0.743

Review 3.  Diagnosis and Treatment of Hyponatremia: Compilation of the Guidelines.

Authors:  Ewout J Hoorn; Robert Zietse
Journal:  J Am Soc Nephrol       Date:  2017-02-07       Impact factor: 10.121

Review 4.  The Emerging Role of Copeptin.

Authors:  R Jalleh; D J Torpy
Journal:  Clin Biochem Rev       Date:  2021-02

Review 5.  Vasopressin and Copeptin in health and disease.

Authors:  Mirjam Christ-Crain
Journal:  Rev Endocr Metab Disord       Date:  2019-09       Impact factor: 6.514

6.  Copeptin in hyponatremia: is there a role for this biomarker in the diagnostic workup?

Authors:  Marco Baldrighi; Luigi Mario Castello; Ettore Bartoli
Journal:  Endocrine       Date:  2018-03-01       Impact factor: 3.633

7.  Natural killer/T-cell lymphoma with concomitant syndrome of inappropriate antidiuretic hormone secretion: A case report and review of literature.

Authors:  Quan-Bo Liu; Rui Zheng
Journal:  World J Clin Cases       Date:  2018-11-06       Impact factor: 1.337

8.  Is copeptin a reliable biomarker of primary monosymptomatic nocturnal enuresis?

Authors:  Hanna Szymanik-Grzelak; Maria Urszula Daniel; Piotr Skrzypczyk; Iwona Kotuła; Małgorzata Pańczyk-Tomaszewska
Journal:  Cent Eur J Immunol       Date:  2019-04-15       Impact factor: 2.085

Review 9.  Copeptin and its role in the diagnosis of diabetes insipidus and the syndrome of inappropriate antidiuresis.

Authors:  Julie Refardt; Bettina Winzeler; Mirjam Christ-Crain
Journal:  Clin Endocrinol (Oxf)       Date:  2019-05-08       Impact factor: 3.478

10.  Copeptin is not useful as a marker of malignant disease in the syndrome of inappropriate antidiuresis.

Authors:  Bettina Winzeler; Michelle Steinmetz; Julie Refardt; Nicole Cesana-Nigro; Milica Popovic; Wiebke Fenske; Mirjam Christ-Crain
Journal:  Endocr Connect       Date:  2020-01       Impact factor: 3.335

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.